494223-70-0

Upstream product

• 494224-49-6 (R)-ethyl 4-(tert-butoxycarbonylamino)-5-oxopentanoate 
• 1380346-97-3 ethyl (4R,5E,7S)-8-(3-(1-benzofuran-2-yl)phenyl)-7-hydroxy-4-((tert-butyloxycarbonyl)amino)-5-octenoate 
• 1393523-60-8 C₂₄H₂₇NO₄*ClH 
• 1380346-99-5 ethyl 4-((2-[(2R)-2-((1E,3S)-4-[3-(1-benzofuran-2-yl)phenyl]-3-hydroxy-1-buten-1-yl)-5-oxo-1-pyrrolidinyl]ethyl)thio)butanoate 
• 1380347-14-7 dimethyl (3-[3-(1-benzofuran-2-yl)phenyl]-2-oxopropyl)phosphonate 

Relevant academic research and scientific papers

Synthesis and evaluation of γ-lactam analogs of PGE2 as EP4 and EP2/EP4 agonists

To identify topically effective EP4 agonists and EP2/EP4 dual agonists with excellent subtype selectivity, further optimization of the 16-phenyl ω-chain moiety of the γ-lactam 5-thia prostaglandin E analog and the 2-mercaptothiazole-4-carboxylic acid anal

REMEDIES FOR DISEASES WITH BONE MASS LOSS HAVING EP sb 4 /sb AGONIST AS THE ACTIVE INGREDIENT

A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP4 agonist as an active ingredient. An EP4 agonist, in which includes a compound